Premium
Is secondary lymphoid‐organ chemokine (SLC/CCL21) much more than a constitutive chemokine?
Author(s) -
Serra H. M.,
BaenaCagnani C. E.,
Eberhard Y.
Publication year - 2004
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2004.00531.x
Subject(s) - ccl21 , chemokine , ccl13 , biology , cxcl13 , immunology , xcl2 , angiogenesis , ccl17 , lymph node stromal cell , c c chemokine receptor type 7 , stromal cell , ccr10 , high endothelial venules , microbiology and biotechnology , lymphatic system , cxcl2 , cxcl10 , chemokine receptor , immune system , cancer research
Chemokines are a superfamily of small cytokines with activities ranging from leukocyte traffick to hematopoiesis, angiogenesis, and tissue organogenesis. Secondary lymphoid‐organ chemokine (SLC/CCL21) was originally reported as a chemokine constitutively expressed by stromal cells and high endothelial venules in secondary lymphoid tissues and endothelium of afferent lymphatics, directing CCR7 + cells. More recently, others and we have demonstrated that SLC/CCL21 is up‐regulated in different skin inflammatory conditions. Thereafter, this molecule is much more than a constitutive chemokine, which could play a role in effector and regulatory immune functions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom